Genocea to Present at 29th Annual Piper Jaffray Healthcare Conference
November 21 2017 - 8:00AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing neoantigen cancer vaccines, today announced that
Chip Clark, president and chief executive officer, will participate
in a fireside chat at the 29th Annual Piper Jaffray Healthcare
Conference on Tuesday, November 28, 2017 at 3:30 p.m. ET in New
York City.
A live webcast of the fireside chat can be accessed by visiting
the "Events and Presentations" tab of the investor relations
section of the Genocea website at http://ir.genocea.com. A
replay of the webcast will be archived for 30 days following the
conference.
About Genocea Biosciences, Inc.Genocea is
harnessing the power of T cell immunity to develop potentially
life-changing vaccines and immunotherapies. While traditional
immunotherapy discovery methods have largely used predictive
methods to propose T cell targets, or antigens, Genocea has
developed ATLAS™, its proprietary technology platform, to identify
clinically relevant antigens of T cells based on actual human
immune responses. Genocea is using ATLAS in immuno-oncology
applications to develop neoantigen cancer vaccines while also
exploring partnership opportunities for general cancer vaccines and
a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea
expects to begin clinical development of its first neoantigen
cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic
alternatives for GEN-003, its Phase 3-ready immunotherapy candidate
for the treatment of genital herpes. For more information, please
visit www.genocea.com.
|
|
|
For
media: |
|
For investors: |
Jennifer LaVin |
|
Jonathan
Poole |
O: 617-715-6687 |
|
O:
617-876-8191 |
jennifer.lavin@genocea.com |
|
jonathan.poole@genocea.com |
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024